8-K
filed February 6, 2025, 6:59 PM ET
CIK 0001479290
M&A
confidence high
sentiment neutral
materiality 0.75
Revance Therapeutics, Inc.: M&A transaction — Crown Laboratories completes acquisition of Revance Therapeutics for $3.65/share
Revance Therapeutics, Inc.
- Crown Labs acquired Revance at $3.65/share cash; ~82% of shares tendered in offer.
- Merger completed Feb 6, 2025; Revance becomes wholly-owned subsidiary.
- 1.75% convertible notes due 2027 now convertible only into $3.65/unit cash (no stock).
- All eight directors resigned; Jeffery Bedard named sole director; new officers appointed.
- Revance common stock to be delisted from Nasdaq and deregistered.
Key facts
Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Revance Therapeutics, Inc. faced acceleration on convertible notes of $1,000 principal amount with U.S. Bank Trust Company, National Association at 1.75% maturing due 2027.
- Instrument
- convertible notes
- Principal
- $1,000 principal amount
- Counterparty
- U.S. Bank Trust Company, National Association
- Rate
- 1.75%
- Maturity
- due 2027
- Event
- acceleration
Exact text from the filing
from and after the Effective Time, the 2027 Convertible Notes are no longer convertible into shares of the Company’s common stock. Rather, a holder’s right to convert each $1,000 principal amount of the 2027 Convertible Notes into shares of the Company’s common stock has been changed to the right to convert such principal amount solely into a number of
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Angus C. Russell resigned as director at Revance Therapeutics, Inc..
- Action
- resigned
- Role
- director
Exact text from the filing
at the Effective Time, each of the directors of the Company (Angus C. Russell, Chris Nolet, Jill Beraud, Vlad Coric, Mark J. Foley, Julian S. Gangolli, Carey O’Connor Kolaja and Olivia C. Ware) resigned as directors of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Chris Nolet resigned as director at Revance Therapeutics, Inc..
- Action
- resigned
- Role
- director
Exact text from the filing
at the Effective Time, each of the directors of the Company (Angus C. Russell, Chris Nolet, Jill Beraud, Vlad Coric, Mark J. Foley, Julian S. Gangolli, Carey O’Connor Kolaja and Olivia C. Ware) resigned as directors of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Vlad Coric resigned as director at Revance Therapeutics, Inc..
- Action
- resigned
- Role
- director
Exact text from the filing
at the Effective Time, each of the directors of the Company (Angus C. Russell, Chris Nolet, Jill Beraud, Vlad Coric, Mark J. Foley, Julian S. Gangolli, Carey O’Connor Kolaja and Olivia C. Ware) resigned as directors of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Julian S. Gangolli resigned as director at Revance Therapeutics, Inc..
- Action
- resigned
- Role
- director
Exact text from the filing
at the Effective Time, each of the directors of the Company (Angus C. Russell, Chris Nolet, Jill Beraud, Vlad Coric, Mark J. Foley, Julian S. Gangolli, Carey O’Connor Kolaja and Olivia C. Ware) resigned as directors of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Nadeem Moiz was appointed as President, Chief Financial Officer and Chief Operating Officer at Revance Therapeutics, Inc..
- Action
- became
- Role
- President, Chief Financial Officer and Chief Operating Officer
Exact text from the filing
the officers of Merger Sub immediately prior to the Effective Time became the officers of the surviving corporation, effective as of the Effective Time. The officers of Merger Sub immediately prior to the Effective Time were Jeffery A Bedard as Chief Executive Officer, Nadeem Moiz as President, Chief Financial Officer and Chief Operating Officer, and Shellie L. Hammock as Executive Vice President, General Counsel and Secretary.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Jill Beraud resigned as director at Revance Therapeutics, Inc..
- Action
- resigned
- Role
- director
Exact text from the filing
at the Effective Time, each of the directors of the Company (Angus C. Russell, Chris Nolet, Jill Beraud, Vlad Coric, Mark J. Foley, Julian S. Gangolli, Carey O’Connor Kolaja and Olivia C. Ware) resigned as directors of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Jeffery A Bedard was appointed as director at Revance Therapeutics, Inc..
- Action
- became
- Role
- director
Exact text from the filing
Jeffery A Bedard became the sole director of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Jeffery A Bedard was appointed as Chief Executive Officer at Revance Therapeutics, Inc..
- Action
- became
- Role
- Chief Executive Officer
Exact text from the filing
the officers of Merger Sub immediately prior to the Effective Time became the officers of the surviving corporation, effective as of the Effective Time. The officers of Merger Sub immediately prior to the Effective Time were Jeffery A Bedard as Chief Executive Officer, Nadeem Moiz as President, Chief Financial Officer and Chief Operating Officer, and Shellie L. Hammock as Executive Vice President, General Counsel and Secretary.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Olivia C. Ware resigned as director at Revance Therapeutics, Inc..
- Action
- resigned
- Role
- director
Exact text from the filing
at the Effective Time, each of the directors of the Company (Angus C. Russell, Chris Nolet, Jill Beraud, Vlad Coric, Mark J. Foley, Julian S. Gangolli, Carey O’Connor Kolaja and Olivia C. Ware) resigned as directors of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Mark J. Foley resigned as director at Revance Therapeutics, Inc..
- Action
- resigned
- Role
- director
Exact text from the filing
at the Effective Time, each of the directors of the Company (Angus C. Russell, Chris Nolet, Jill Beraud, Vlad Coric, Mark J. Foley, Julian S. Gangolli, Carey O’Connor Kolaja and Olivia C. Ware) resigned as directors of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Carey O’Connor Kolaja resigned as director at Revance Therapeutics, Inc..
- Action
- resigned
- Role
- director
Exact text from the filing
at the Effective Time, each of the directors of the Company (Angus C. Russell, Chris Nolet, Jill Beraud, Vlad Coric, Mark J. Foley, Julian S. Gangolli, Carey O’Connor Kolaja and Olivia C. Ware) resigned as directors of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Shellie L. Hammock was appointed as Executive Vice President, General Counsel and Secretary at Revance Therapeutics, Inc..
- Action
- became
- Role
- Executive Vice President, General Counsel and Secretary
Exact text from the filing
the officers of Merger Sub immediately prior to the Effective Time became the officers of the surviving corporation, effective as of the Effective Time. The officers of Merger Sub immediately prior to the Effective Time were Jeffery A Bedard as Chief Executive Officer, Nadeem Moiz as President, Chief Financial Officer and Chief Operating Officer, and Shellie L. Hammock as Executive Vice President, General Counsel and Secretary.
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
Revance Therapeutics, Inc. underwent a change of control involving Crown Laboratories, Inc. and Reba Merger Sub, Inc. for $3.65 per Share (closed 2025-02-06).
- Action
- change of control
- Counterparty
- Crown Laboratories, Inc. and Reba Merger Sub, Inc.
- Consideration
- $3.65 per Share
- Closing
- 2025-02-06
Exact text from the filing
Notes, in effect on the applicable conversion date (subject to any adjustments pursuant to the terms of the Indenture), with each unit of Reference Property consisting of $3.65 in cash. The foregoing descriptions of the Indenture and the transactions contemplated thereby are subject to and qualified in their entirety by reference to the full text of the
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.